$ZBH earnings report

Zimmer Biomet Announces Third Quarter 2026 Financial Results. AlphAI read Zimmer Biomet Holdings's third quarter 2026 filing as solid. 2 quarters are on record below.

third quarter 2026

AlphAI · Earnings readZBH · third quarter 2026 · ended September 30, 2026

Zimmer Biomet Announces Third Quarter 2026 Financial Results

✓Solid quarter

Third quarter net sales increased 3.1% on a reported basis and 3.7% on a constant currency basis, adjusted diluted EPS was consistent with the prior year period, operating cash flow and free cash flow increased, and the Company raised full-year organic constant-currency sales growth and adjusted EPS guidance. GAAP diluted EPS decreased 13.8%, while reported and adjusted operating profit margins declined.

Revenue
$2.06B
3.1 % y/y
United States - three months ended September 30
$1.21B
3.6 % y/y
Gross margin · GAAP
63.1 %
Projected Year Ending December 31, 2026 outlook
2026 Reported Revenue Change 4.4% - 4.9%; 2026 Constant Currency Revenue Change 4.1% - 4.6%; 2026 Organic Constant Currency Revenue Change 3.0% - 3.5%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net Sales - three months ended September 30GAAP$2.06B–3.1 %
Net Sales constant currency change - three months ended September 30non-GAAP3.7 %–3.7 %
Gross Profit - three months ended September 30GAAP$1.30B––
Gross margin - three months ended September 30GAAP63.1 %––
Adjusted gross profit - three months ended September 30non-GAAP$1.48B––
Adjusted gross margin - three months ended September 30non-GAAP71.7 %––
Operating expenses - three months ended September 30GAAP1,755.4––
Operating Profit - three months ended September 30GAAP307.6––
Operating profit margin - three months ended September 30GAAP14.9 %––
Adjusted operating profit - three months ended September 30non-GAAP$518.8M––
Adjusted operating profit margin - three months ended September 30non-GAAP25.1 %––
Earnings before income taxes - three months ended September 30GAAP230.1––
Net Earnings - three months ended September 30GAAP192.9––
Net Earnings of Zimmer Biomet Holdings, Inc. - three months ended September 30GAAP$191.6M––
Adjusted Net Earnings of Zimmer Biomet Holdings, Inc. - three months ended September 30non-GAAP$362.8M––
Diluted earnings per common share - three months ended September 30GAAP$ 1.00–a decrease of 13.8%
Adjusted diluted earnings per common share - three months ended September 30non-GAAP$ 1.90–consistent with the prior year period
Effective tax rate - three months ended September 30GAAP16.2 %––
Adjusted effective tax rate - three months ended September 30non-GAAP17.6 %––
Net cash provided by operating activities - three months ended September 30GAAP$560M––
Free cash flow - three months ended September 30non-GAAP$372.4M––
Net Sales - nine months ended September 30GAAP$6.33B–5.7 %
Net Sales constant currency change - nine months ended September 30non-GAAP5.0 %–5.0 %
Net Sales organic constant currency change - nine months ended September 30non-GAAP3.5 %–3.5 %
Gross Profit - nine months ended September 30GAAP$4.03B––
Gross margin - nine months ended September 30GAAP63.7 %––
Adjusted gross profit - nine months ended September 30non-GAAP$4.55B––
Adjusted gross margin - nine months ended September 30non-GAAP71.9 %––
Operating expenses - nine months ended September 30GAAP5,319.7––
Operating Profit - nine months ended September 30GAAP1,006.8––
Operating profit margin - nine months ended September 30GAAP15.9 %––
Adjusted operating profit - nine months ended September 30non-GAAP$1.65B––
Adjusted operating profit margin - nine months ended September 30non-GAAP26.1 %––
Net Earnings of Zimmer Biomet Holdings, Inc. - nine months ended September 30GAAP$628.1M––
Adjusted Net Earnings of Zimmer Biomet Holdings, Inc. - nine months ended September 30non-GAAP$1.17B––
Diluted earnings per common share - nine months ended September 30GAAP$ 3.25––
Adjusted diluted earnings per common share - nine months ended September 30non-GAAP$ 6.06––
Effective tax rate - nine months ended September 30GAAP19.8 %––
Adjusted effective tax rate - nine months ended September 30non-GAAP17.9 %––
Net cash provided by operating activities - nine months ended September 30GAAP$1.37B––
Free cash flow - nine months ended September 30non-GAAP$926.5M––

Segments

SegmentRevenueq/qy/y
United States - three months ended September 30Constant currency sales change was 3.6 %.$1.21B–3.6 %
International - three months ended September 30Constant currency sales change was 3.9 %.857.2M–2.4 %
Knees - three months ended September 30Constant currency sales change was (2.6 ).767.5M–(3.1 ) %
Hips - three months ended September 30Constant currency sales change was 7.0.536.5M–6.0 %
S.E.T. - three months ended September 30Constant currency sales change was 7.1. S.E.T. includes Sports Medicine, Biologics, Foot and Ankle, Upper Extremities, Trauma, Craniomaxillofacial and Thoracic.578.3M–6.8
Technology & Data, Bone Cement and Surgical - three months ended September 30Constant currency sales change was 13.0.180.6M–11.9
United States - nine months ended September 30Constant currency sales change was 5.9 %; organic constant currency sales change was 3.8 %.$3.65B–5.9 %
International - nine months ended September 30Constant currency sales change was 3.8; organic constant currency sales change was 3.2 %.2.67B–5.3
Knees - nine months ended September 30Constant currency sales change was (0.2 ); organic constant currency sales change was (0.2 ).2.42B–0.6
Hips - nine months ended September 30Constant currency sales change was 5.1; organic constant currency sales change was 5.1.1.62B–5.5
S.E.T. - nine months ended September 30Constant currency sales change was 9.9; organic constant currency sales change was 4.1. S.E.T. includes Sports Medicine, Biologics, Foot and Ankle, Upper Extremities, Trauma, Craniomaxillofacial and Thoracic.1.73B–10.5
Technology & Data, Bone Cement and Surgical - nine months ended September 30Constant currency sales change was 15.5; organic constant currency sales change was 15.5.551.8M–16.0

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

Projected Year Ending December 31, 2026 outlook

  • Revenue2026 Reported Revenue Change 4.4% - 4.9%; 2026 Constant Currency Revenue Change 4.1% - 4.6%; 2026 Organic Constant Currency Revenue Change 3.0% - 3.5%
  • NoteForeign Currency Exchange Impact +0.25%
  • NoteAdjusted Diluted EPS $8.50- $8.60

Capital returns

  • Dividends paid to stockholders were $(139.2 ) for the nine months ended September 30, 2026, compared with $(142.8 ) for the nine months ended September 30, 2025.
  • Repurchase of common stock was $(579.3 ) for the nine months ended September 30, 2026, compared with $(237.0 ) for the nine months ended September 30, 2025.

What drove it

  • Third quarter total net sales increased 3.7% on a constant-currency basis.
  • Hips grew 7.0 on a constant-currency basis in the third quarter.
  • S.E.T. grew 7.1 on a constant-currency basis in the third quarter.
  • Technology & Data, Bone Cement and Surgical grew 13.0 on a constant-currency basis in the third quarter.
  • The Company stated that Hips, S.E.T. and Technology & Data, Bone Cement and Surgical, representing two-thirds of its book of business, grew at upper single digit or double-digit rates.
  • For the nine-month period, Technology & Data, Bone Cement and Surgical grew 15.5 on both constant-currency and organic constant-currency bases.
  • For the nine-month period, S.E.T. growth included a 5.8 % Paragon 28 impact, with organic constant-currency growth of 4.1 %.

Concerns

  • Knees sales declined (3.1 ) % on a reported basis and (2.6 ) on a constant-currency basis in the third quarter.
  • Third-quarter GAAP diluted earnings per share decreased 13.8% to $1.00.
  • Third-quarter operating profit was 307.6 versus 351.3, and operating profit margin was 14.9 % versus 17.6 %.
  • Third-quarter adjusted operating profit was $ 518.8 versus $ 531.0, and adjusted operating profit margin was 25.1 % versus 26.5 %.
  • Third-quarter gross margin was 63.1 % versus 63.2 %, and adjusted gross margin was 71.7 % versus 72.6 %.
  • Cash and cash equivalents declined to $ 399.9 from $ 591.9, while net debt increased to $ 7,104.3 from $ 6,927.2.

What to watch

  • Execution against updated 2026 reported revenue change guidance of 4.4% - 4.9%.
  • Execution against updated 2026 organic constant currency revenue change guidance of 3.0% - 3.5%.
  • Delivery against updated adjusted diluted EPS guidance of $8.50- $8.60.
  • Whether Knees sales recover from the third-quarter constant-currency decline of (2.6 ).
  • The trajectory of adjusted gross margin and adjusted operating profit margin, which were 71.7 % and 25.1 % in the third quarter.
  • The contribution from Paragon 28, which represented a 5.8 % impact on nine-month S.E.T. constant-currency growth and a 1.5 % impact on nine-month total constant-currency growth.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 399.9 as of September 30, 2026, compared with $ 591.9 as of December 31, 2025.
  • Debt, both current and long-term, was $ 7,504.2 as of September 30, 2026, compared with $ 7,519.1 as of December 31, 2025.
  • Net debt was $ 7,104.3 as of September 30, 2026, compared with $ 6,927.2 as of December 31, 2025.
  • Receivables, net were 1,816.0 as of September 30, 2026, compared with 1,704.4 as of December 31, 2025.
  • Inventories were 2,367.2 as of September 30, 2026, compared with 2,286.4 as of December 31, 2025.
  • Net cash provided by operating activities was $ 1,367.2 for the nine months ended September 30, 2026, compared with $ 1,179.7 for the prior-year period.
  • Net cash used in investing activities was $(893.1 ) for the nine months ended September 30, 2026, compared with $(1,653.7 ) for the prior-year period.
  • Net cash used in financing activities was $(667.5 ) for the nine months ended September 30, 2026, compared with 1,223.0 for the prior-year period.

Analysis

Zimmer Biomet delivered third-quarter net sales of $2.063 billion, up 3.1% on a reported basis and 3.7% on a constant-currency basis. The growth profile was led by Technology & Data, Bone Cement and Surgical, up 13.0 on a constant-currency basis, and Hips and S.E.T., up 7.0 and 7.1, respectively. Knees was the exception, with sales down (3.1 ) % reported and (2.6 ) on a constant-currency basis. U.S. sales increased 3.6 % and international sales increased 3.9 % on a constant-currency basis.

Profitability was lower on both a reported and adjusted basis in the quarter. Gross margin was 63.1 % compared with 63.2 %, while adjusted gross margin was 71.7 % compared with 72.6 %. Operating profit was 307.6 compared with 351.3, and operating profit margin was 14.9 % compared with 17.6 %. Adjusted operating profit was $ 518.8 compared with $ 531.0, and adjusted operating profit margin was 25.1 % compared with 26.5 %. GAAP diluted earnings per share declined 13.8% to $1.00, while adjusted diluted earnings per share held at $1.90.

Cash generation strengthened. Third-quarter net cash provided by operating activities was $ 560.0 compared with $ 418.7, and free cash flow was $ 372.4 compared with $ 277.6. For the nine-month period, net cash provided by operating activities reached $ 1,367.2 and free cash flow was $ 926.5. The Company repurchased $(579.3 ) of common stock and paid $(139.2 ) of dividends during the first nine months. Cash and cash equivalents were $ 399.9 at September 30, 2026, while net debt was $ 7,104.3.

For the first nine months, net sales were $ 6,326.6, up 5.7 % reported, 5.0 % at constant currency and 3.5 % on an organic constant-currency basis. S.E.T. grew 9.9 at constant currency but 4.1 % organically, reflecting a 5.8 % Paragon 28 impact. The Company increased its full-year outlook for reported revenue change to 4.4% - 4.9%, constant-currency revenue change to 4.1% - 4.6%, organic constant-currency revenue change to 3.0% - 3.5%, and adjusted diluted EPS to $8.50- $8.60. The updated guidance places attention on sustaining growth in the faster-growing franchises while improving the margin trends and restoring Knees growth.

Management, verbatim

We are very pleased with our solid third quarter results, growing net sales 3.7% on a constant-currency basis and generating strong operating and free cash flow.

Ivan Tornos, Chairman, President and CEO of Zimmer Biomet

Our Hips, S.E.T. and Technology & Data, Bone Cement and Surgical franchises – representing two-thirds of our book of business – grew at upper single digit or double-digit rates, validating the progress of our diversification strategy, the strength of our innovation engine and the significant strides we are making in commercial execution.

Ivan Tornos, Chairman, President and CEO of Zimmer Biomet

This broad-based performance gives us confidence to raise our full-year organic constant-currency sales growth and adjusted EPS guidance.

Ivan Tornos, Chairman, President and CEO of Zimmer Biomet

Not in the filing

stated, not guessed
  • Previous-release outlook for comparison was not provided; therefore, no actual-versus-prior-guidance comparison is available.
  • Prior-quarter figures and sequential changes for reported metrics were not provided.
  • Full-year 2026 guidance for gross margin, operating expenses and tax rate was not provided.
  • Third-quarter dividend payments and common-stock repurchases were not separately provided.
  • GAAP diluted EPS guidance and a reconciliation of adjusted diluted EPS guidance to GAAP were not available without unreasonable efforts, as stated by the Company.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readZBH · second quarter 2026 · ended June 30, 2026

Zimmer Biomet Announces Second Quarter 2026 Financial Results

✓Solid quarter

Second quarter net sales increased 4.8% on a reported basis and 4.0% on an organic constant currency basis, while the company raised its full-year 2026 revenue and adjusted diluted EPS guidance. Adjusted diluted EPS was consistent with the prior year period, and International Knees sales declined.

Revenue
$2.18B
4.8% y/y
United States, three months ended June 30, 2026
$1.24B
5.6% y/y
EPS · non-GAAP
$2.07
consistent with the prior year period y/y
Projected Year Ending December 31, 2026 outlook
2026 Reported Revenue Change: 3.9% - 4.9%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$2.18B–4.8%
Net sales constant currency changenon-GAAP4.7%–4.7%
Net sales organic constant currency changenon-GAAP4.0%–4.0%
Net earningsGAAP$198.3M––
Adjusted net earningsnon-GAAP$399.6M––
Diluted earnings per shareGAAP$1.03–33.8%
Adjusted diluted earnings per sharenon-GAAP$2.07–consistent with the prior year period
Operating cash flowGAAP$447.9M––
Free cash flownon-GAAP$308.3M––
Net sales, six months ended June 30, 2026GAAP$4.26B–7.0%
Net sales constant currency change, six months ended June 30, 2026non-GAAP5.7%–5.7%
Net sales organic constant currency change, six months ended June 30, 2026non-GAAP3.4%–3.4%

Segments

SegmentRevenueq/qy/y
United States, three months ended June 30, 2026Constant currency change was 5.6% and organic constant currency change was 4.6%.$1.24B–5.6%
International, three months ended June 30, 2026Constant currency change was 3.5% and organic constant currency change was 3.1%.$937M–3.7%
Knees, three months ended June 30, 2026Constant currency change was 0.1% and organic constant currency change was 0.1%.828.9M–0.4%
Knees United States, three months ended June 30, 2026Constant currency change was 1.4% and organic constant currency change was 1.4%.$455M–1.4%
Knees International, three months ended June 30, 2026Constant currency change was (1.5) and organic constant currency change was (1.5).374M–(0.9)
Hips, three months ended June 30, 2026Constant currency change was 5.1% and organic constant currency change was 5.1%.562.7M–5.0%
Hips United States, three months ended June 30, 2026Constant currency change was 5.9% and organic constant currency change was 5.9%.288.5M–5.9%
Hips International, three months ended June 30, 2026Constant currency change was 4.2% and organic constant currency change was 4.2%.274.1M–4.0%
S.E.T., three months ended June 30, 2026Constant currency change was 6.2% and organic constant currency change was 3.4%.586M–6.4%
Technology & Data, Bone Cement and Surgical, three months ended June 30, 2026Constant currency change was 21.5% and organic constant currency change was 21.5%.199.4M–21.1%
United States, six months ended June 30, 2026Constant currency change was 7.1% and organic constant currency change was 3.9%.$2.45B–7.1%
International, six months ended June 30, 2026Constant currency change was 3.8% and organic constant currency change was 2.8%.1.81B–6.8%
Knees, six months ended June 30, 2026Constant currency change was 0.9% and organic constant currency change was 0.9%.1.66B–2.4%
Hips, six months ended June 30, 2026Constant currency change was 4.2% and organic constant currency change was 4.2%.1.09B–5.3%
S.E.T., six months ended June 30, 2026Constant currency change was 11.3% and organic constant currency change was 2.6%.1.15B–12.5%
Technology & Data, Bone Cement and Surgical, six months ended June 30, 2026Constant currency change was 16.8% and organic constant currency change was 16.8%.371.2M–18.0%

Projected Year Ending December 31, 2026 outlook

  • Revenue2026 Reported Revenue Change: 3.9% - 4.9%
  • NoteForeign Currency Exchange Impact: +0.5%
  • Note2026 Constant Currency Revenue Change: 3.4% - 4.4%
  • Note2026 Organic Constant Currency Revenue Change: 2.25% - 3.25%
  • NoteAdjusted Diluted EPS: $8.47 - $8.59

Capital returns

  • Increased share repurchase expectations of up to $1 billion of its common stock during fiscal year 2026.

What drove it

  • Technology & Data, Bone Cement and Surgical sales increased 21.1% on a reported basis and 21.5% on an organic constant currency basis in the second quarter.
  • S.E.T. sales increased 6.4% on a reported basis and 3.4% on an organic constant currency basis in the second quarter.
  • Hips sales increased 5.0% on a reported basis and 5.1% on an organic constant currency basis in the second quarter.
  • The company cited healthy underlying markets, go-to-market changes progressing as planned and continued momentum from its innovation cycle.
  • The company received U.S. FDA 510(k) clearance and completed first cases of the next generation ROSA® Shoulder System.

Concerns

  • Knees sales increased 0.4% on a reported basis and 0.1% on an organic constant currency basis in the second quarter.
  • International Knees sales declined (0.9) on a reported basis and declined (1.5) on both a constant currency and organic constant currency basis in the second quarter.
  • Adjusted diluted EPS of $2.07 was consistent with the prior year period.
  • Gross margin, operating expenses, operating income, tax rate, cash and debt were not included in the supplied filing text.

What to watch

  • Execution against updated 2026 reported revenue change guidance of 3.9% - 4.9%.
  • Execution against updated 2026 organic constant currency revenue change guidance of 2.25% - 3.25%.
  • Delivery against updated adjusted diluted EPS guidance of $8.47 - $8.59.
  • Performance of Knees, including International Knees sales.
  • Execution of up to $1 billion of common-stock repurchases during fiscal year 2026.
  • Commercial progress from go-to-market changes and the innovation cycle, including the next generation ROSA® Shoulder System.

Balance sheet and cash flow

  • Generated $447.9 million in operating cash flow in the second quarter.
  • Generated $308.3 million of free cash flow in the second quarter.

Analysis

Zimmer Biomet reported second-quarter net sales of $2.177 billion, up 4.8% on a reported basis, 4.7% on a constant currency basis and 4.0% on an organic constant currency basis. For the six months ended June 30, 2026, net sales were $4,263.7 million, up 7.0% reported, 5.7% constant currency and 3.4% organic constant currency. The quarter therefore reflects continued underlying growth, with reported growth modestly ahead of organic constant currency growth.

Product-category performance was led by Technology & Data, Bone Cement and Surgical, where second-quarter sales were 199.4 million and increased 21.1% reported and 21.5% organic constant currency. S.E.T. sales were 586.0 million, increasing 6.4% reported and 3.4% organic constant currency, while Hips sales were 562.7 million, increasing 5.0% reported and 5.1% organic constant currency. Knees remained the slowest category at 828.9 million, up 0.4% reported and 0.1% organic constant currency; International Knees sales declined (0.9) reported and (1.5) on both constant currency measures.

The United States generated $1,239.9 million of second-quarter sales, up 5.6% reported and 4.6% organic constant currency. International sales were $937.0 million, up 3.7% reported and 3.1% organic constant currency. The geographic and category tables show growth across the principal regions and most product categories, but also show a material divergence between the higher-growth Technology & Data, Bone Cement and Surgical category and the nearly flat Knees category.

Profitability data reported in the supplied text included net earnings of $198.3 million, adjusted net earnings of $399.6 million, GAAP diluted EPS of $1.03 and adjusted diluted EPS of $2.07. GAAP diluted EPS increased 33.8%, while adjusted diluted EPS was consistent with the prior year period. The supplied text did not provide gross margin, operating income, operating expenses or tax rate, limiting assessment of the underlying drivers of the GAAP-to-adjusted earnings difference and margin movement.

Cash generation was $447.9 million of operating cash flow and $308.3 million of free cash flow in the second quarter. The company increased expected common-stock repurchases to up to $1 billion during fiscal year 2026. It also updated full-year guidance upward: reported revenue change is now 3.9% - 4.9%, constant currency revenue change is 3.4% - 4.4%, organic constant currency revenue change is 2.25% - 3.25%, and adjusted diluted EPS is $8.47 - $8.59. Management attributed the update to a strong first half, healthy underlying markets, progress in go-to-market changes and innovation momentum.

Management, verbatim

We delivered strong second quarter results with solid top- and bottom-line performance and continued progress on our key growth drivers and commercial transformation.

Ivan Tornos, Chairman, President and CEO of Zimmer Biomet

With a strong first half, healthy underlying markets, go-to-market changes progressing as planned and continued momentum from our innovation cycle, we are raising our revenue and adjusted EPS guidance for the year.

Ivan Tornos, Chairman, President and CEO of Zimmer Biomet

Not in the filing

stated, not guessed
  • Prior-quarter net sales, net earnings, adjusted net earnings, diluted EPS, adjusted diluted EPS, operating cash flow and free cash flow.
  • Prior-year net sales dollar amount, net earnings, adjusted net earnings, diluted EPS, adjusted diluted EPS, operating cash flow and free cash flow.
  • Gross profit and gross margin.
  • Operating expenses and operating income.
  • GAAP net income margin and adjusted net income margin.
  • Tax expense and tax rate.
  • Cash, cash equivalents, marketable securities, total debt and net debt.
  • Dividends.
  • Share repurchase amount executed during the second quarter.
  • Capital expenditures or additions to instruments and other property, plant and equipment.
  • Reconciliation tables for adjusted net earnings, adjusted diluted EPS and free cash flow are not included in the supplied filing text.
  • Prior-release outlook for comparison with actual reported results.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ZBH earnings dates

When is Zimmer Biomet Holdings's next earnings date?
AlphAI has no date for ZBH yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.